博瑞医药：关于公司部分产品拟中选国家药品接续采购的公告

Group 1 - The core announcement is that Borui Pharmaceutical's wholly-owned subsidiary, Borui Pharmaceutical (Suzhou) Co., Ltd., has its products selected for the national centralized procurement program, with a procurement period extending until December 31, 2028 [2] - The selected products include Agatroban injection, Micafungin sodium for injection, Oseltamivir phosphate dry suspension, and Oseltamivir phosphate capsules [2] - The total sales of these four products for the first three quarters of 2025 are projected to be 88.8475 million yuan, accounting for 10.16% of the company's revenue [2]